Skinvisible Reported Earnings

Skinvisible (SKVI) reported a loss of $0.05 per share on revenue of $0.01 million for the . .

SKINVISIBLE PHARMACEUTICALS Inc., a wholly owned subsidiary of Skinvisible Inc., is a research-and-development company whose primary business objective is to license its proprietary formulations with Invisicare to pharmaceutical and cosmeceutical companies as well as assisting companies in revitalizing or enhancing their existing skin care products. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the patent.